Re: Economic Evaluation of Everolimus Versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma After Failure of First-Line Sunitinib Editorial Comment

被引：0
|
作者：
Penson, David F.
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 188卷 / 01期
关键词：
D O I：
10.1016/j.juro.2012.03.096
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：68 / 69
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
    Sheng, Xinan
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Li, Siming
    Tang, Bixia
    Mao, Lili
    Lian, Bin
    Wang, Xuan
    Yan, Xieqiao
    Guo, Jun
    ONCOTARGET, 2016, 7 (19) : 27044 - 27054
  • [32] Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
    Hsieh, James J.
    Chen, David
    Wang, Patricia I.
    Marker, Mahtab
    Redzematovic, Almedina
    Chen, Ying-Bei
    Selcuklu, S. Duygu
    Weinhold, Nils
    Bouvier, Nancy
    Huberman, Kety H.
    Bhanot, Umesh
    Chevinsky, Michael S.
    Patel, Parul
    Pinciroli, Patrizia
    Won, Helen H.
    You, Daoqi
    Viale, Agnes
    Lee, William
    Hakimi, A. Ari
    Berger, Michael F.
    Socci, Nicholas D.
    Cheng, Emily H.
    Knox, Jennifer
    Voss, Martin H.
    Voi, Maurizio
    Motzer, Robert J.
    EUROPEAN UROLOGY, 2017, 71 (03) : 405 - 414
  • [33] Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib
    Grassi, Paolo
    Verzoni, Elena
    Porcu, Luca
    Iacovelli, Roberto
    de Braud, Filippo
    Procopio, Giuseppe
    THERAPEUTIC ADVANCES IN UROLOGY, 2015, 7 (02) : 59 - 68
  • [34] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [35] Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan
    Al-Rabayah, Abeer A.
    Sawalha, Razan
    Al Froukh, Rawan Fawzi
    Al-Bawab, Rand
    Jaddoua, Saad M.
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2021, 12 (04) : 566 - 573
  • [36] Sorafenib in Patients With Metastatic Renal Cell Carcinoma Refractory to Either Sunitinib or Bevacizumab Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2011, 185 (03): : 809 - 809
  • [37] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Ruiz-Morales, Jose Manuel
    Swierkowski, Marcin
    Wells, J. Connor
    Fraccon, Anna Paola
    Pasini, Felice
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Sim, Hao-Wen
    Sliwczynsk, Andrzej
    Ptak-Chmielewska, Aneta
    Teter, Zbigniew
    Beuselinck, Benoit
    Wood, Lori A.
    Yuasa, Takeshi
    Pezaro, Carmel
    Rini, Brian I.
    Szczylik, Cezary
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN JOURNAL OF CANCER, 2016, 65 : 102 - 108
  • [38] Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?
    Buti, Sebastiano
    Bersanelli, Melissa
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (16) : 1858 - +
  • [39] First-line treatment of metastatic renal cell carcinoma
    Bruchbacher, Andreas
    Netsch, Christopher
    Gross, Andreas J. J.
    UROLOGIE, 2023, 62 (08): : 830 - 839
  • [40] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Negrier, S.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345